Journal
CANCER
Volume 125, Issue 17, Pages 2910-2914Publisher
WILEY
DOI: 10.1002/cncr.32197
Keywords
-
Categories
Funding
- National Institutes of Health [U54CA225088]
- Ludwig Center at Harvard
Ask authors/readers for more resources
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors for patients with PCPs. With continued successful responses, it is proposed that BRAF (and MEK) inhibitors be evaluated for the neoadjuvant treatment of patients with PCPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available